IXICO has provided a positive trading update for the six months to March 2021. The company expects H1/21 revenue growth of 8% to £4.9m, which we view as strong performance given the pandemic backdrop. Further, the order book remains strong at £19.0m with £9.4m of new contracts signed in the half and despite the recently announced lost Huntington's disease (HD) revenues, in respect of which IXICO has removed £7.1m from the orderbook. Considering this, we believe IXICO shares are discounting a gre ....
26 Apr 2021
Cenkos: IXICO Plc - Resilient performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc - Resilient performance
IXICO Plc (IXI:LON) | 8.4 0 (-3.2%) | Mkt Cap: 4.05m
- Published:
26 Apr 2021 -
Author:
Chris Donnellan -
Pages:
9
IXICO has provided a positive trading update for the six months to March 2021. The company expects H1/21 revenue growth of 8% to £4.9m, which we view as strong performance given the pandemic backdrop. Further, the order book remains strong at £19.0m with £9.4m of new contracts signed in the half and despite the recently announced lost Huntington's disease (HD) revenues, in respect of which IXICO has removed £7.1m from the orderbook. Considering this, we believe IXICO shares are discounting a gre ....